Plain English Summary
Background and study aims
Inflammatory Bowel Disease (IBD) is an autoimmune disease of the digestive system with unknown causes that has two main types: Ulcerative Colitis (UC) and Crohn’s Disease (CD). CD and UC are not well managed with current drugs either because of limited effectiveness or significant side effects. BT-11 is a new drug targeting UC and CD. Its effectiveness has been demonstrated in mouse models of IBD. The aim of this study is to assess the safety, tolerability and pharmacokinetic profile of BT-11 (movement of drug through the body) after single and multiple increasing oral doses in healthy volunteers.
Who can participate?
Healthy male and female volunteers aged 18 to 65 years, inclusive
What does the study involve?
Participants are randomly allocated to receive either BT-11 or a placebo (dummy drug) as a single ascending dose (SAD) or multiple ascending dose (MAD) to measure the safety of the drug. The total maximum duration on study for SAD participants is about 35 days (up to 28-day screening period, 3-day treatment/confinement period, and 4-day follow-up). The total maximum duration on study for MAD participants is about 44 days (up to 28 days screening, 8 days treatment/confinement, and 8 days follow-up).
What are the possible benefits and risks of participating?
The patients were not expected to receive any direct medical benefits from the study. The information developed in this study may help people with Inflammatory Bowel Disease. As this drug is new, it was not known what all the possible side effects may be and there may be unknown risks. However, based on animal data, no specific safety concerns have been identified.
Where is the study run from?
CMAX Clinical Research (Australia)
When is the study starting and how long is it expected to run for?
June 2018 to October 2018
Who is funding the study?
Landos Biopharma Inc. (USA)
Who is the main contact?
Josep Bassaganya-Riera
Trial website
Contact information
Type
Scientific
Primary contact
Dr Josep Bassaganya-Riera
ORCID ID
Contact details
1800 Kraft Drive SW
Suite 216
Blacksburg
24060
United States of America
Type
Public
Additional contact
Ms Jyoti Chauhan
ORCID ID
http://orcid.org/0000-0002-3837-3000
Contact details
1800 Kraft Drive SW
Suite 216
Blacksburg
24060
United States of America
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
BT-11-1a; ACTRN12618001210268
Study information
Scientific title
A randomized, placebo-controlled, sequential single and multiple dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of oral BT-11 in healthy adult male and female volunteers
Acronym
Study hypothesis
BT-11 is a first-in-class modulator of LANCL2 signaling. Through its action on LANCL2, BT-11 intervention will suppress the pathology of IBD patients at 2 levels: by decreasing the production of inflammatory mediators and increasing anti-inflammatory molecules in the GI tract.
Ethics approval
Bellberry Human Research Ethics Committee, 129 Glen Osmond Rd, Eastwood SA 5063, Tel: +61 (0)8 8361 3222, 06/07/2018
Study design
Randomized placebo-controlled sequential single and multiple dose-escalation study
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Other
Trial type
Treatment
Patient information sheet
Condition
Ulcerative colitis and Crohn's disease
Intervention
This is a two-stage, single-center, double-blinded, randomized, placebo-controlled study of BT-11 in healthy male and female volunteers. The two stages are a single ascending dose (SAD), and multiple ascending dose (MAD).
All participants who were dosed were assigned a randomization number in accordance with the randomization schedule after confirmation of eligibility on Day 1.
The single ascending dose (SAD) cohorts consist of five groups of eight healthy male and female participants per cohort, each receiving a single oral dose of BT-11 or placebo in a 6-hour fasted state for a total n = 8, with n= 6 receiving active and n=2 receiving placebo. Five different doses were used for SAD (7.7 mg/kg, 25 mg/kg, 50 mg/kg, 75 mg/kg, and 100 mg/kg).
The multiple ascending dose (MAD) cohorts will consist of three cohorts of ten healthy male and female participants, each receiving an oral dose of BT-11 or placebo once daily for seven days, with n = 8 receiving active and n = 2 receiving placebo. For MAD three different doses were used (7.7 mg/kg, 50 mg/kg, and 100 mg/kg).
SAD Follow up: Total maximum duration on study for SAD participants will be approximately 35 days (up to 28-day screening period, 3-day treatment/confinement period, and 4- day follow-up period).
MAD Follow up: Total maximum duration on study for MAD participants will be approximately 44 days (up to 28 days screening, 8 days treatment/confinement, and 8 days follow-up).
Intervention type
Drug
Phase
Phase I
Drug names
BT-11
Primary outcome measure
The safety and tolerability of BT-11 after single and multiple ascending oral dose administration in healthy volunteers, measured during 4 days follow up (SAD), and 8 days follow up (MAD)
Secondary outcome measures
The pharmacokinetic profile of BT-11 after single and multiple ascending oral dose administration in healthy volunteers, measured using blood samples during 4 days follow up (SAD), and 8 days follow up (MAD)
Overall trial start date
12/06/2018
Overall trial end date
23/10/2018
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Healthy male and female volunteers aged 18 to 65 years, inclusive
2. Body weight 65 - 85 kg
3. Body Mass Index (weight in kg divided by square of height in meters) 19-31 kg/m2, inclusive
4. Male volunteers must agree to abstain, between dosing and 30 days post-dosing, from sexual intercourse with pregnant or lactating women and, if sexually active with a female partner, to use a condom in addition to his female partner’s use of another form of contraception (e.g., IUD, diaphragm, oral contraceptive, injectable progesterone contraceptive, subdermal implant contraceptive, or tubal ligation). A male practicing abstinence is also acceptable
5. Female subjects of child-bearing potential, with a fertile male sexual partner, should be willing to use adequate contraception from Day 1 until 30 days after the follow-up visit. Adequate contraception is defined as a combination of two methods of contraception known to be effective, such as an intrauterine device with a barrier method, or two different barrier methods.. Also, total abstinence, in accordance with the lifestyle of the subject, is acceptable
6. Volunteer agrees not to take any concomitant medications, including prescriptions or over-the-counter (OTC) medications during the interval from 3 days prior to dosing until after the last PK blood draw for the study
7. Volunteer agrees not to consume alcohol during the interval from 3 days prior to dosing until after the last PK blood draw for the study
8. Volunteer is able to communicate effectively with study personnel
9. Volunteer is able to understand and comply with protocol and investigative site requirements, instructions, and restrictions.
10. Volunteer has read, confirmed understanding of, and signed the written informed consent form after the nature of the study and all essential elements of the informed consent document have been fully explained and all of the Volunteer’s questions have been answered to his or her satisfaction, prior to initiation of any study procedures
Participant type
Healthy volunteer
Age group
Adult
Gender
Both
Target number of participants
70
Total final enrolment
70
Participant exclusion criteria
1. Any clinically significant abnormality identified in the screening history, physical examination (including Vital Signs), laboratory testing, or electrocardiographic testing. Repeat testing of vital signs to confirm the value is allowed. Up to two repeat tests are permitted to confirm eligibility
2. An excessive fall in blood pressure on orthostatic testing at screening or Day –1 (i.e., a fall in systolic blood pressure > 25 mmHg or in diastolic blood pressure > 15 mmHg)
3. Any 12-lead ECG finding at screening or on Day –1 that may, in the opinion of the Investigator, compromise interpretation of ECGs for cardiac safety assessment or complicate interpretation of events that may occur post-dose (e.g., QT not accurately measurable, conduction abnormalities)
4. Positive test for HIV, hepatitis B surface antigen, or hepatitis C antibody
5. Any clinically significant cardiac, pulmonary, renal, metabolic, neurologic, or other medical, behavioural, or genetic condition
6. Any condition that places the volunteer at significantly increased risk or may risk compromise of study objectives
7. Use of prescription or non-prescription drugs 3 days or 5 half-lives (whichever is longer) prior to dosing to after last PK draw
8. Use of herbal supplements within 3 days or 5 half-lives (whichever is longer) prior to the first dose of study drug to after last PK draw
9. Use of alcohol within 72 hours prior to first dose of study drug
10. History of drug or alcohol abuse (by DSM-IV definition) within 3 months prior to screening
11. Positive urine drug screen (including cotinine, cannabis, cocaine, opiates, amphetamines, and other tests as determined by Investigator). Repeating analyses will be allowed if the PI suspects that there might be false positive results
12. Volunteer has a contraindication to blood sampling or is considered to have insufficient peripheral venous access
13. Volunteer has donated blood or blood products in volumes of 450 mL or more within 30 days prior to study enrollment
14. Volunteer has been previously exposed to BT-11
15. Volunteer has participated in a study of any investigational drug, device, biologic, or other agent within 30 days prior to study enrollment.
16. Volunteer has known hypersensitivity to BT-11 or any of its constituents
17. Volunteer has any disorder (e.g., psychiatric, addictive) that, in Investigator’s judgement, may compromise his/her ability to provide legal written informed consent
Recruitment start date
06/07/2018
Recruitment end date
22/09/2018
Locations
Countries of recruitment
Australia
Trial participating centre
CMAX Clinical Research
s: 5/18a North Terrace
Adelaide SA
5000
Australia
Sponsor information
Organisation
Landos Biopharma Inc.
Sponsor details
1800 Kraft Drive SW
Suite 216
Blacksburg
24060
United States of America
Sponsor type
Industry
Website
Funders
Funder type
Industry
Funder name
Landos Biopharma Inc.
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
The protocol is not publicly available yet but high level results are publicly available on sponsor’s website (www.landosbiopharma.com). Planned publication in a high-impact peer reviewed journal.
IPD sharing statement
The datasets generated during and/or analysed during the current study are/will be available upon request from Jyoti Chauhan and Josep Bassaganya-Riera.
Intention to publish date
01/07/2019
Participant level data
Available on request
Basic results (scientific)
Publication list
2019 results in: https://www.ncbi.nlm.nih.gov/pubmed/31077582 (added 09/01/2020)